Yoshiya Yamada
YOU?
Author Swipe
View article: Impact of Pain Management Interventions and Radiation Therapy on Pain Control and Treatment Accuracy in Spine Radiation for Metastasis
Impact of Pain Management Interventions and Radiation Therapy on Pain Control and Treatment Accuracy in Spine Radiation for Metastasis Open
View article: FLASH Stereotactic Body Radiation Therapy for Spine Tumors Using a Single-Energy Proton Pristine Bragg Peak Delivery Technique
FLASH Stereotactic Body Radiation Therapy for Spine Tumors Using a Single-Energy Proton Pristine Bragg Peak Delivery Technique Open
BP-FLASH SBRT is a promising treatment for challenging spinal cord cancers, which achieved ultra-high-dose rates for FLASH effect and maintained the same dosimetry quality as the CONV-IMPT plans.
View article: FLASH stereotactic body radiation therapy for spine tumors using a single-energy proton pristine Bragg peak delivery technique
FLASH stereotactic body radiation therapy for spine tumors using a single-energy proton pristine Bragg peak delivery technique Open
View article: FLASH STEREOTACTIC BODY RADIATION THERAPY FOR SPINE TUMORS USING A SINGLE-ENERGY PROTON PRISTINE BRAGG PEAK DELIVERY TECHNIQUE
FLASH STEREOTACTIC BODY RADIATION THERAPY FOR SPINE TUMORS USING A SINGLE-ENERGY PROTON PRISTINE BRAGG PEAK DELIVERY TECHNIQUE Open
View article: Prospective evaluation of patient-reported outcomes of invisible ink tattoos for the delivery of external beam radiation therapy: the PREFER trial
Prospective evaluation of patient-reported outcomes of invisible ink tattoos for the delivery of external beam radiation therapy: the PREFER trial Open
Introduction Invisible ink tattoos (IITs) avoid cosmetic permanence of visible ink tattoos (VITs) while serving as more reliable landmarks for radiation setup than tattooless setups. This trial evaluated patient-reported preference and fea…
View article: Automated planning of stereotactic spine re-irradiation using cumulative dose limits
Automated planning of stereotactic spine re-irradiation using cumulative dose limits Open
View article: T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy
T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy Open
The specificity of plasma volume was higher than that of conventional size measurements, suggesting that dynamic contrast-enhanced MR imaging is a powerful tool to discriminate between treatment success and failure.
View article: EPCO-01. THE GENOMIC LANDSCAPE OF BRAIN METASTASIS
EPCO-01. THE GENOMIC LANDSCAPE OF BRAIN METASTASIS Open
BACKGROUND The prognosis for patients with brain metastasis (BM) is devastating, while the underlying biology of BM development remains poorly understood. Identification of genomic biomarkers can offer promising opportunities for predictio…
View article: BIOM-01. PROGNOSTIC IMPLICATIONS OF SMALL CELL LUNG CANCER (SCLC) TRANSCRIPTIONAL SUBTYPING FOR CENTRAL NERVOUS SYSTEM (CNS) METASTASES
BIOM-01. PROGNOSTIC IMPLICATIONS OF SMALL CELL LUNG CANCER (SCLC) TRANSCRIPTIONAL SUBTYPING FOR CENTRAL NERVOUS SYSTEM (CNS) METASTASES Open
BACKGROUND Small cell lung cancer (SCLC) is characterized by a high propensity for brain metastases (BM) and is associated with a poor prognosis. Subtypes characterized by high versus low neuroendocrine states (expressing ASCL1 or NEUROD1)…
View article: Radiation Therapy for Colorectal Liver Metastasis: The Effect of Radiation Therapy Dose and Chemotherapy on Local Control and Survival
Radiation Therapy for Colorectal Liver Metastasis: The Effect of Radiation Therapy Dose and Chemotherapy on Local Control and Survival Open
View article: Radiotherapy for Mobile Spine and Sacral Chordoma: A Critical Review and Practical Guide from the Spine Tumor Academy
Radiotherapy for Mobile Spine and Sacral Chordoma: A Critical Review and Practical Guide from the Spine Tumor Academy Open
Chordomas are rare tumors of the embryologic spinal cord remnant. They are locally aggressive and typically managed with surgery and either adjuvant or neoadjuvant radiation therapy. However, there is great variability in practice patterns…
View article: Data from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Data from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implicat…
View article: Supplementary Table 2 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Supplementary Table 2 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
PDF - 63KB, Prospective studies combining ipilimumab and radiation therapy for patients with unresectable and/or metastatic melanoma.
View article: Data from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Data from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implicat…
View article: Supplementary Table 2 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Supplementary Table 2 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
PDF - 63KB, Prospective studies combining ipilimumab and radiation therapy for patients with unresectable and/or metastatic melanoma.
View article: Supplementary Table 1 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Supplementary Table 1 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
PDF - 59KB, Frequency of immune-related adverse events (irAEs) in the present study and in a previous study.
View article: Supplementary Table 1 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Supplementary Table 1 from Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma Open
PDF - 59KB, Frequency of immune-related adverse events (irAEs) in the present study and in a previous study.
View article: Table S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Treatment-related adverse events
View article: Table S4 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S4 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Flow cytometry result summary
View article: Figure S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Figure S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Study design
View article: Table S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Treatment-related adverse events
View article: Table S4 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S4 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Flow cytometry result summary
View article: Figure S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Figure S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Study design
View article: Figure S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Figure S2 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Flow dot plots
View article: Data from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Data from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Purpose:Immune checkpoint inhibition (ICI) alone is not active in mismatch repair–proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus…
View article: Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Radiation treatment summary
View article: Table S3 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S3 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Gene mutations in responder patients
View article: Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S1 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Radiation treatment summary
View article: Data from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Data from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Purpose:Immune checkpoint inhibition (ICI) alone is not active in mismatch repair–proficient (MMR-P) metastatic colorectal cancer (mCRC), nor does radiotherapy alone result in objective systemic benefit. However, combined radiotherapy plus…
View article: Table S3 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
Table S3 from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer Open
Gene mutations in responder patients